BOSTON--(BUSINESS WIRE)--Nov 5, 2018--Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 6,153 shares of its common stock to one new employee and 40,000 restricted stock units (RSUs) to another new employee. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $5.18 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on November 1, 2018 and vest at a rate of 20% on the one-year anniversary of his or her date of hire, and thereafter, at a rate of 5% of the shares subject to the options at the end of each successive three-month period, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date. The RSUs will vest at a rate of 25% annually on the anniversary of his or her date of hire, provided that the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.

Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit  www.verastem.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181105005976/en/

CONTACT: Verastem Oncology:

Brian Sullivan, +1 781-469-1636

Senior Director, Corporate Development

bsullivan@verastem.com

or

Media:

FleishmanHillard

Adam Silverstein, +1 917-697-9313

media@verastem.com

or

Investors:

Argot Partners

Joseph Rayne, +1 617-340-6075

joseph@argotpartners.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL

SOURCE: Verastem, Inc.

Copyright Business Wire 2018.

PUB: 11/05/2018 04:40 PM/DISC: 11/05/2018 04:40 PM

http://www.businesswire.com/news/home/20181105005976/en

Copyright Business Wire 2018.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.